At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Camlipixantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Safety of Camlipixant in Male and Female Participants Aged 18-75 Years of Age With Hepatic Impairment Compared to Matched Healthy Participants With Normal Hepatic Function
In Brief
A Phase 1 clinical trial evaluating Camlipixant for Cough. Completed, enrolled 32 participants across 3 sites.
Detailed Summary
The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCough
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedJan 2024
Enrollment StartFeb 2024
Primary CompletionDec 2024
Study CompletionDec 2024
TodayJul 2026
First PostedJan 25, 2024
Enrollment StartFeb 2, 2024
Primary CompletionDec 17, 2024
Study CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.4 years ago
Interventions
Camlipixantdrug
Camlipixant was administered.